questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
One-carbon group transferases
Methyltransferases
Protein Methyltransferases
Histone méthyltransférases
Histone-lysine N-methyltransferase
Histone-lysine N-methyltransferase : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Histone-lysine N-methyltransferase : Questions médicales les plus fréquentes",
"headline": "Histone-lysine N-methyltransferase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Histone-lysine N-methyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Histone-lysine N-methyltransferase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Histone méthyltransférases",
"url": "https://questionsmedicales.fr/mesh/D000076983",
"about": {
"@type": "MedicalCondition",
"name": "Histone méthyltransférases",
"code": {
"@type": "MedicalCode",
"code": "D000076983",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.555.500.800.200"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Histone-lysine N-methyltransferase",
"alternateName": "Histone-Lysine N-Methyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D011495",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jasmin Mecinović",
"url": "https://questionsmedicales.fr/author/Jasmin%20Mecinovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Abbas H K Al Temimi",
"url": "https://questionsmedicales.fr/author/Abbas%20H%20K%20Al%20Temimi",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Danny C Lenstra",
"url": "https://questionsmedicales.fr/author/Danny%20C%20Lenstra",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Paul B White",
"url": "https://questionsmedicales.fr/author/Paul%20B%20White",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. Floris.Rutjes@ru.nl."
}
},
{
"@type": "Person",
"name": "Ping Qian",
"url": "https://questionsmedicales.fr/author/Ping%20Qian",
"affiliation": {
"@type": "Organization",
"name": "Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Streptococcal and Staphylococcus aureus prosthetic joint infections: are they really different?",
"datePublished": "2022-06-17",
"url": "https://questionsmedicales.fr/article/35715754",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12879-022-07532-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evolutionary history of Staphylococcus aureus influences antibiotic resistance evolution.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37494936",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cub.2023.06.082"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is neighborhood deprivation index a risk factor for Staphylococcus aureus infections?",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37478909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajic.2023.07.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37199616",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/spectrum.04918-22"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pediatric deep venous thrombosis associated with Staphylococcus aureus osteomyelitis.",
"datePublished": "2023-04-30",
"url": "https://questionsmedicales.fr/article/37159886",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3855/jidc.17026"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "One-carbon group transferases",
"item": "https://questionsmedicales.fr/mesh/D019875"
},
{
"@type": "ListItem",
"position": 6,
"name": "Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D008780"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protein Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D011496"
},
{
"@type": "ListItem",
"position": 8,
"name": "Histone méthyltransférases",
"item": "https://questionsmedicales.fr/mesh/D000076983"
},
{
"@type": "ListItem",
"position": 9,
"name": "Histone-lysine N-methyltransferase",
"item": "https://questionsmedicales.fr/mesh/D011495"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Histone-lysine N-methyltransferase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Histone-lysine N-methyltransferase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Histone-lysine N-methyltransferase",
"description": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?\nQuels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux N-méthyltransférases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Histone-lysine N-methyltransferase",
"description": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?\nLes symptômes sont-ils spécifiques à une maladie ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes peuvent-ils évoluer avec le temps ?\nLes symptômes sont-ils visibles à l'examen physique ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Histone-lysine N-methyltransferase",
"description": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes exercices physiques aident-ils à prévenir les dysfonctionnements ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Histone-lysine N-methyltransferase",
"description": "Quels traitements ciblent les N-méthyltransférases ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Histone-lysine N-methyltransferase",
"description": "Quelles complications peuvent survenir avec des dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications neurologiques possibles ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications liées aux N-méthyltransférases ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Histone-lysine N-methyltransferase",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies chroniques sont-elles des facteurs de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Staphylococcus+aureus&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des méthodes de chromatographie peuvent être employés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être nécessaires pour évaluer les modifications épigénétiques."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux N-méthyltransférases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones peuvent servir de marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer ces anomalies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'expression génique peuvent entraîner divers symptômes, selon le tissu."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils spécifiques à une maladie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils peuvent varier selon la maladie et le type de tissu affecté."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines dysfonctions peuvent entraîner des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils évoluer avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'évolution des symptômes dépend de la progression de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils visibles à l'examen physique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les symptômes ne sont pas visibles et nécessitent des tests spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents chimiques et toxines peuvent influencer la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être utiles pour les personnes à risque génétique élevé."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer la santé épigénétique et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les exercices physiques aident-ils à prévenir les dysfonctionnements ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut avoir un impact positif sur la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les N-méthyltransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des N-méthyltransférases sont en cours de développement."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique pourrait corriger les anomalies liées aux N-méthyltransférases."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comme tout traitement, des effets secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité à long terme dépend de la maladie et de la réponse individuelle au traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des dysfonctionnements ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des cancers et d'autres maladies génétiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison de modifications épigénétiques."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux N-méthyltransférases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et l'exposition à des agents environnementaux sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dysfonctionnement enzymatique augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques sont-elles des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent prédisposer à des dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques peuvent augmenter le risque de dysfonctionnement."
}
}
]
}
]
}
Staphylococci and streptococci are the most frequent pathogens isolated from prosthetic joint infections (PJIs). The aim of this study was to analyze the outcome of streptococcal and methicillin-susce...
All monomicrobial streptococcal and MSSA PJIs managed in a French Referral Center (2010-2017) were sampled from the prospective PJIs cohort study. The primary outcome of interest was the cumulative re...
Two hundred and nine patients with 91 streptococcal and 132 staphylococcal infections were analyzed. Patients with streptococcal PJI were older, and infection was more frequently hematogenous. Reinfec...
Reinfection-free survival after DAIR and SAT was better for patients with streptococcal than those with MSSA PJIs. No difference was observed after prosthesis exchange....
Antibiotic resistance often confers a fitness cost to the resistant cell and thus raises key questions of how resistance is maintained in the absence of antibiotics and, if lost, whether cells are gen...
We assessed the association between neighborhood area deprivation index (ADI) and community-onset (co) and hospital-onset (ho) Staphylococcus aureus infection....
Demographic and clinical characteristics of patients admitted to 5 adult hospitals in the mid-Atlantic between 2016 and 2018 were obtained. The association of ADI with methicillin-resistant (MRSA) and...
Overall, increasing ADI was associated with higher odds of co- and ho-MRSA and MSSA infection. In univariate analysis, Black race was associated with 44% greater odds of ho-MRSA infection (odds ratio ...
The area deprivation index is associated with community and hospital-onset MRSA and MSSA infections....
Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resi...
Our objective was to evaluate clinical features of children with deep venous thrombosis (DVT) and acute hematogenous osteomyelitis (AHO) caused by Staphylococcus aureus....
We analyzed 4 years of medical records of patients with AHO and DVT caused by Staphylococcus aureus (S. aureus) and compared clinical and biochemical characteristics of AHO with and without DVT, as we...
DVT was found in 19/87 AHO individuals (22%). The median age was 9 years (range: 0.5-15 years). 74% (14/19) patients were boys. Methicillin-susceptible Staphylococcus aureus (MSSA) was present in 58% ...
Over 20% of patients with S. aureus AHO developed DVT. MSSA accounted for more than half of the cases. DVT was completely resolved in more than half of the cases after 3 weeks of anticoagulant medicat...
Staphylococcus aureus bacteremia is common and associated with fatality rates approximating 25%. We provide a brief overview of S. aureus bacteremia from a clinical and microbiological lens and review...
Apurinic/apyrimidinic (AP) endonucleases are key enzymes involved in the repair of abasic sites and DNA strand breaks. Complete genome analysis of Staphylococcus aureus identified a single AP endonucl...
Despite clear benefit of improved outcomes in adults, the impact of infectious diseases (ID) consultation for Staphylococcus aureus bacteremia in children remains understudied....
To assess the impact of pediatric ID consultation on management and outcomes, we conducted a cohort study of children with S. aureus bacteremia at St. Louis Children's Hospital from 2011 to 2018. We a...
Of 306 patients with S. aureus bacteremia, 193 (63%) received ID consultation. ID consultation was associated with increased adherence to all QCIs, including proof-of-cure blood cultures, indicated la...
For children with S. aureus bacteremia, ID consultation improved adherence to QCIs, some of which were associated with improved clinical outcomes....
In children with Staphylococcus aureus bacteremia, consultation by an infectious diseases (ID) physician improved adherence to established quality-of-care indicators (QCIs). The current literature reg...
Endoscopic endonasal approach (EEA) procedures are inherently contaminated due to direct access through the nasopharyngeal mucosa. The reported rate of postoperative meningitis in EEA procedures is 0....
All adult patients who underwent EEA resection at our institution from 2013 to 2021 were retrospectively reviewed. Patients with preoperative cerebrospinal fluid infections were excluded. Data includi...
Of 483 patients identified (mean age, 51 years; range, 18-90 years; 274 [56.7%] female), 80 (16.6%) had a positive preoperative methicillin-resistant Staphylococcus aureus (MRSA)/methicillin-sensitive...
Postoperative rates of meningitis after EEA surgery were not significantly changed based on MRSA/MSSA colonization status of the patient or preoperative decolonization. The utility of preoperative tes...
Multi-drug-resistant Staphylococcus aureus infections necessitate novel antibiotic development. D-3263, a transient receptor potential melastatin member 8 (TRPM8) agonist, has potential antineoplastic...